All In Biotech

Drug Trial Radar · NCT04116541

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

455

Planned (sponsor's estimate)

Start

Jan 28, 2020

Primary completion

Oct 2026

Study completion Oct 2027

Sponsor

Lead sponsor
Centre Leon BerardAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multicenter, open-label, biology driven, phase II study using a sequential Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted Therapy (MTT) in independent and parallel cohorts of treatment. Patients will be assigned to a treatment cohort based on molecular alterations/characteristics detected on tumor sample from primary tumor or metastatic lesion. In this protocol, several MTTs treatment cohorts are planned. This study is designed with the flexibility to open new MTTs treatment cohorts and to close existing MTTs treatment cohorts that demonstrate no clinical benefit. Each treatment cohort will be driven separately even though procedures, quality control and reporting, will be common. The protocol will be amended in order to include new treatments or combinations that emerge as being of interest for patients with advanced/metastatic cancers. All eligible patients will receive study drugs as long as patient experiences clinical benefit in the opinion of the investigator, or until unacceptable toxicity, or until symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status, or withdrawal of consent. Patients will be permitted to continue study treatment after progressive disease according to RECIST v1.1 if they meet all of the following criteria and following validation of the Sponsor: * Evidence of clinical benefit as assessed by the investigators, * Absence of symptoms and signs (including worsening of laboratory values; e.g., new or worsening hypercalcemia) that indicate unequivocal progression of disease, * No decline in ECOG Performance Status (PS) that can be attributed to disease progression.

Conditions

  • Malignant Solid Tumor

Interventions

  • HDM201Drug

    HDM201 120mg, Every 3 weeks, Per os

  • RibociclibDrug

    Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os

  • CabozantinibDrug

    Cabozantinib, 60 mg /day, continuous, Per os

  • AlectinibDrug

    Alectinib, 600mg twice daily, Per os

  • RegorafenibDrug

    Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os

  • TrametinibDrug

    Trametinib 2 mg/day, continuous, Per os

  • DabrafenibDrug

    Dabrafenib 150 mg twice daily, Per os

  • AvapritinibDrug

    300 mg/day,continuous, Per os

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free rate after 3 months (12 weeks) of treatmentTime frame: 3 months (12 weeks)

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • INSTITUT DE CANCEROLOGIE DE L'OUEST Pays de Loire

    Angers, France · Not yet recruiting

  • Institut Bergonié

    Bordeaux, France · Recruiting

  • Centre François Baclesse

    Caen, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • Centre Antoine LACASSAGNE

    Nice, France · Recruiting

  • Institut Curie

    Paris, France · Not yet recruiting

  • Centre Henri Becquerel

    Rouen, France · Not yet recruiting

  • Centre Paul Strauss

    Strasbourg, France · Recruiting

  • Institut de Cancérologie de Strasbourg

    Strasbourg, France · Terminated

  • CHU Strasbourg - Hôpital de Hautepierre

    Strasbourg, France · Recruiting

  • Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.